Menu

Pipeline Overview

PRODUCT** Planned
Indication
Pre-clinical Phase i/ii Phase iii NDA/Marketed
GI & Inflammation
Donnatal® IBS and acute enterocolitis***
U.S. CO-PROMOTION
EnteraGam® Chronic diarrhea and loose stools****
U.S. EXCLUSIVE LICENSE
Esomeprazole Strontium DR Capsules GERD and other GI conditions*****
U.S. COMMERCIALIZATION LICENSE
TALICIA™ (RHB-105) H. pylori infections
RHB-104 Crohn's disease
NTM infections
BEKINDA®
(RHB-102)
Gastroenteritis & gastritis
IBS-D
RHB-106 Bowel cleanser
Oncology -
GI/Inflammation
YELIVA® (ABC294640) Multiple indications
MESUPRON Pancreatic Cancer
Other
RIZAPORT®
(RHB-103)
Migraine
* Estimated timeline/indication in the pipeline is subject to changes in development plans and regulatory requirements/clarifications, including complementary /additional studies ** BEKINDA®, YELIVA®, TALICIA™ and RIZAPORT® are proposed tradenames which are subject to FDA review and approval *** For full prescribing information see: www.Donnatal.com; ****EnteraGam® is a medical food which must be administered under medical supervision ***** for full prescribing information see: dailymed.nlm.nih.gov

Company Profile

RedHill Biopharma (NASDAQ: RDHL) (Tel-Aviv Stock Exchange: RDHL) is a specialty biopharmaceutical company focused primarily on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases, including cancer.

Read more